Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit
Authors:
- Francesco SaccàFSFrancesco Saccà
- Fabio AcquavivaFAFabio Acquaviva
- Guido CarlomagnoGCGuido Carlomagno
- Alessandra DenaroADAlessandra Denaro
- Anna GuacciAGAnna Guacci
- Angela MarsiliAMAngela Marsili
- Giorgia PuorroGPGiorgia Puorro
- 10 November 2010
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 26 (4) , 739-742
Abstract
Objective of the study was to test the efficacy, safety, and tolerability of two single doses of Epoetin alfa in patients with Friedreich's ataxia. Ten patients were treated subcutaneously with 600 IU/kg for the first dose, and 3 months later with 1200 IU/kg. Epoetin alfa had no acute effect on frataxin, whereas a delayed and sustained increase in frataxin was evident at 3 months after the first dose (+35%; P < 0.05), and up to 6 months after the second dose (+54%; P < 0.001). The treatment was well tolerated and did not affect hematocrit, cardiac function, and neurological scale. Single high dose of Epoetin alfa can produce a considerably larger and sustained effect when compared with low doses and repeated administration schemes previously adopted. In addition, no hemoglobin increase was observed, and none of our patients required phlebotomy, indicating lack of erythropoietic effect of single high dose of erythropoietin. © 2010 Movement Disorder SocietyKeywords
Funding Information
- “Associazione il cuore in un dono” Cardito, Naples, Italy
- “Associazione Italiana per la lotta alle Sindromi Atassiche (AISA) sez. Campania”, Napoli, Italy
- Janssen-Cilag SpA
This publication has 19 references indexed in Scilit:
- Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapyEuropean Journal of Clinical Investigation, 2009
- Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neuronsProceedings of the National Academy of Sciences, 2009
- Erythropoietin modulation of astrocyte water permeability as a component of neuroprotectionProceedings of the National Academy of Sciences, 2009
- Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trialMovement Disorders, 2008
- Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriersMolecular Genetics and Metabolism, 2008
- Phlebotomies or erythropoietin injections allow mobilization of iron stores in a mouse model mimicking intensive care anemiaCritical Care Medicine, 2008
- Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietinAnnals of Neurology, 2007
- Iron–sulfur protein maturation in human cells: evidence for a function of frataxinHuman Molecular Genetics, 2004
- Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin After Single and Multiple Doses in Healthy VolunteersThe Journal of Clinical Pharmacology, 2004
- Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of Friedreich ataxia patients and carriersJournal of Neurology, Neurosurgery & Psychiatry, 2004